Antimicrobial resistance in Gram-negative bacilli in Spain : an experts' view
©The Author 2022. Published by Sociedad Española de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/)..
BACKGROUND: Antibiotic resistance in Gram-negative bacilli poses a serious problem for public health. In hospitals, in addition to high mortality rates, the emergence and spread of resistance to practically all antibiotics restricts therapeutic options against serious and frequent infections.
OBJECTIVE: The aim of this work is to present the views of a group of experts on the following aspects regarding resistance to antimicrobial agents in Gram-negative bacilli: 1) the current epidemiology in Spain, 2) how it is related to local clinical practice and 3) new therapies in this area, based on currently available evidence.
METHODS: After reviewing the most noteworthy evidence, the most relevant data on these three aspects were presented at a national meeting to 99 experts in infectious diseases, clinical microbiology, internal medicine, intensive care medicine, anaesthesiology and hospital pharmacy.
RESULTS AND CONCLUSIONS: Subsequent local debates among these experts led to conclusions in this matter, including the opinion that the approval of new antibiotics makes it necessary to train the specialists involved in order to optimise how they use them and improve health outcomes; microbiology laboratories in hospitals must be available throughout a continuous timetable; all antibiotics must be available when needed and it is necessary to learn to use them correctly; and the Antimicrobial Stewardship Programs (ASP) play a key role in quickly allocating the new antibiotics within the guidelines and ensure appropriate use of them.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:36 |
|---|---|
| Enthalten in: |
Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia - 36(2023), 1 vom: 26. Feb., Seite 65-81 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Retamar-Gentil, P [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-Bacterial Agents |
|---|
| Anmerkungen: |
Date Completed 24.01.2023 Date Revised 17.02.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.37201/req/119.2022 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM350227985 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM350227985 | ||
| 003 | DE-627 | ||
| 005 | 20231226044526.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.37201/req/119.2022 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1167.xml |
| 035 | |a (DE-627)NLM350227985 | ||
| 035 | |a (NLM)36510684 | ||
| 035 | |a (PII)retamar13dec2022 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Retamar-Gentil, P |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Antimicrobial resistance in Gram-negative bacilli in Spain |b an experts' view |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.01.2023 | ||
| 500 | |a Date Revised 17.02.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a ©The Author 2022. Published by Sociedad Española de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/). | ||
| 520 | |a BACKGROUND: Antibiotic resistance in Gram-negative bacilli poses a serious problem for public health. In hospitals, in addition to high mortality rates, the emergence and spread of resistance to practically all antibiotics restricts therapeutic options against serious and frequent infections | ||
| 520 | |a OBJECTIVE: The aim of this work is to present the views of a group of experts on the following aspects regarding resistance to antimicrobial agents in Gram-negative bacilli: 1) the current epidemiology in Spain, 2) how it is related to local clinical practice and 3) new therapies in this area, based on currently available evidence | ||
| 520 | |a METHODS: After reviewing the most noteworthy evidence, the most relevant data on these three aspects were presented at a national meeting to 99 experts in infectious diseases, clinical microbiology, internal medicine, intensive care medicine, anaesthesiology and hospital pharmacy | ||
| 520 | |a RESULTS AND CONCLUSIONS: Subsequent local debates among these experts led to conclusions in this matter, including the opinion that the approval of new antibiotics makes it necessary to train the specialists involved in order to optimise how they use them and improve health outcomes; microbiology laboratories in hospitals must be available throughout a continuous timetable; all antibiotics must be available when needed and it is necessary to learn to use them correctly; and the Antimicrobial Stewardship Programs (ASP) play a key role in quickly allocating the new antibiotics within the guidelines and ensure appropriate use of them | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Antimicrobial resistance | |
| 650 | 4 | |a Enterobacterales | |
| 650 | 4 | |a Multiresistance | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a Anti-Infective Agents |2 NLM | |
| 700 | 1 | |a Cantón, R |e verfasserin |4 aut | |
| 700 | 1 | |a Abril López de Medrano, V |e verfasserin |4 aut | |
| 700 | 1 | |a Barberán, J |e verfasserin |4 aut | |
| 700 | 1 | |a Canut Blasco, A |e verfasserin |4 aut | |
| 700 | 1 | |a Dueñas Gutiérrez, C |e verfasserin |4 aut | |
| 700 | 1 | |a García-Vidal, C |e verfasserin |4 aut | |
| 700 | 1 | |a Larrosa Escartín, N |e verfasserin |4 aut | |
| 700 | 1 | |a Lora-Tamayo, J |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez Marcos, F J |e verfasserin |4 aut | |
| 700 | 1 | |a Martín Ruíz, C |e verfasserin |4 aut | |
| 700 | 1 | |a Pasquau Liaño, J |e verfasserin |4 aut | |
| 700 | 1 | |a Rascado, P |e verfasserin |4 aut | |
| 700 | 1 | |a Sanz Peláez, O |e verfasserin |4 aut | |
| 700 | 1 | |a Yagüe Girao, G |e verfasserin |4 aut | |
| 700 | 1 | |a Horcajada, J P |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia |d 1997 |g 36(2023), 1 vom: 26. Feb., Seite 65-81 |w (DE-627)NLM090649028 |x 1988-9518 |7 nnns |
| 773 | 1 | 8 | |g volume:36 |g year:2023 |g number:1 |g day:26 |g month:02 |g pages:65-81 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.37201/req/119.2022 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 36 |j 2023 |e 1 |b 26 |c 02 |h 65-81 | ||